# ZELSUVMI (berdazimer) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/berdazimer

> The FDA approved ZELSUVMI (berdazimer), sponsored by Pelthos Therapeutics Inc. (PTHS), on January 5, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is ZELSUVMI (berdazimer) FDA approved?

Yes. The FDA approved ZELSUVMI (berdazimer), sponsored by Pelthos Therapeutics Inc. (PTHS), on January 5, 2024. SEC Form 10-K: "This IP portfolio provides material coverage for our platform technologies, licensed products and product candidates, in addition to ZELSUVMI, which was approved by the FDA on January 5, 2024." [Calendar and source filings](https://sec-api.dev/pdufa/berdazimer)

Source: SEC Form 10-K, accession 0000886163-25-000012, https://www.sec.gov/Archives/edgar/data/886163/000088616325000012/lgnd-20241231.htm (retrieved 2026-11-12). Last confirmed 2026-03-19. Cite: https://sec-api.dev/pdufa/berdazimer#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ZELSUVMI (berdazimer) |
| Codes | SB206 |
| Sponsor | Pelthos Therapeutics Inc. (PTHS) https://sec-api.dev/companies/pths/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### January 5, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-28, last confirmed 2026-03-19.
- SEC Form 10-K (accession 0001919246-26-000013): "- We depend heavily on the commercial success of ZELSUVMI, which was approved by the FDA in January 2024, which we have only recently launched in the United States in July 2025." https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- SEC Form 10-K (accession 0001919246-26-000013): "We depend heavily on the commercial success of ZELSUVMI, which was approved by the FDA in January 2024, which we have only recently launched in the United States." https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001753926-25-001606): "Highlights Commercially Launched Zelsuvmi was FDA approved In January 2024, and commercially launched in July 2025 as the first and only at-home treatment aimed to revolutionize how MC is treated today for patients ≥ 1 year old Significant Unmet Need and Sizeable Market Opportunity Large market potential, with up to 6M new cases annually." https://www.sec.gov/Archives/edgar/data/1919246/000175392625001606/g084975_ex99-1.htm
- SEC Form 10-K (accession 0000886163-25-000012): "This IP portfolio provides material coverage for our platform technologies, licensed products and product candidates, in addition to ZELSUVMI, which was approved by the FDA on January 5, 2024." https://www.sec.gov/Archives/edgar/data/886163/000088616325000012/lgnd-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/berdazimer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZELSUVMI (berdazimer) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/berdazimer

```bibtex
@misc{secapidev_pdufa_berdazimer_20261116,
  title        = {ZELSUVMI (berdazimer) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/berdazimer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_berdazimer_20261116","title":"ZELSUVMI (berdazimer) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/berdazimer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
